RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Calliditas Therapeutics - Stock

Calliditas Therapeutics ROCE 2024

Calliditas Therapeutics ROCE

-1.17

Ticker

CALTX.ST

ISIN

SE0010441584

WKN

A2JP36

In 2024, Calliditas Therapeutics's return on capital employed (ROCE) was -1.17, a 115.5% increase from the -0.54 ROCE in the previous year.

Calliditas Therapeutics Aktienanalyse

What does Calliditas Therapeutics do?

Calliditas Therapeutics AB was founded in 2004 and is headquartered in Stockholm, Sweden. The company's goal is to develop innovative therapies for rare diseases and treat patients worldwide. The company is divided into two main business areas: clinical development and commercial products. The clinical development area focuses on identifying, developing, and marketing drugs for the treatment of kidney and liver diseases, as well as autoimmune diseases. The commercial products area distributes the developed medications. Calliditas' business model is based on the discovery and exploration of therapies for rare diseases. The company divides its pipeline into different product categories such as kidney and liver diseases, as well as autoimmune diseases. It is expected that this pipeline will make further progress over time and bring several products to market. Currently, Calliditas is in Phase 3 of clinical trials for Nefecon, a medication for the treatment of IgA nephropathy. IgA nephropathy is a rare kidney disease in which immunoglobulin A deposits in the kidneys can cause inflammation and damage. Nefecon is being developed to reduce the production of IgA and thereby reduce inflammation in the kidneys. Calliditas is also in Phase 2 of clinical trials for Atimmune, a medication for the treatment of autoimmune diseases. Atimmune aims to modulate the immune system to treat autoimmune diseases naturally. In addition, Calliditas is currently working on another medication for the treatment of liver diseases called FT-4202. FT-4202 is intended to increase the production of hemoglobin and thereby alleviate the symptoms of sickle cell anemia. Calliditas has an experienced team of researchers, clinicians, and salespeople dedicated to the development of medications for rare diseases. The company collaborates closely with experts in the field of kidney and liver diseases, as well as autoimmune diseases, to improve the development and marketing of its products. The company has also formed partnerships with other companies and industry stakeholders to support its research and development efforts. For example, Calliditas has entered into an agreement with Everest Medicines Ltd., a Chinese biotech company specializing in rare diseases, to market and distribute Nefecon in China. Overall, Calliditas has a promising pipeline of medications for the treatment of rare diseases. The company is well positioned to succeed in the coming years and improve the lives of patients around the world. Calliditas Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Calliditas Therapeutics's Return on Capital Employed (ROCE)

Calliditas Therapeutics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Calliditas Therapeutics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Calliditas Therapeutics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Calliditas Therapeutics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Calliditas Therapeutics stock

What is the ROCE (Return on Capital Employed) of Calliditas Therapeutics this year?

The ROCE of Calliditas Therapeutics is -1.17 undefined this year.

How has the ROCE (Return on Capital Employed) of Calliditas Therapeutics developed compared to the previous year?

The ROCE of Calliditas Therapeutics has increased by 115.5% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Calliditas Therapeutics?

A high Return on Capital Employed (ROCE) indicates that Calliditas Therapeutics has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Calliditas Therapeutics?

A low ROCE (Return on Capital Employed) can indicate that Calliditas Therapeutics has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Calliditas Therapeutics impact the company?

An increase in the ROCE of Calliditas Therapeutics can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Calliditas Therapeutics affect the company?

A decrease in ROCE of Calliditas Therapeutics can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Calliditas Therapeutics?

Some factors that can affect Calliditas Therapeutics's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Calliditas Therapeutics so important for investors?

The ROCE of Calliditas Therapeutics is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Calliditas Therapeutics take to improve the ROCE?

To improve the ROCE, Calliditas Therapeutics can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Calliditas Therapeutics pay?

Over the past 12 months, Calliditas Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Calliditas Therapeutics is expected to pay a dividend of 0 SEK.

What is the dividend yield of Calliditas Therapeutics?

The current dividend yield of Calliditas Therapeutics is .

When does Calliditas Therapeutics pay dividends?

Calliditas Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Calliditas Therapeutics?

Calliditas Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Calliditas Therapeutics?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Calliditas Therapeutics located?

Calliditas Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Calliditas Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Calliditas Therapeutics from 7/8/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 7/8/2024.

When did Calliditas Therapeutics pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Calliditas Therapeutics in the year 2023?

In the year 2023, Calliditas Therapeutics distributed 0 SEK as dividends.

In which currency does Calliditas Therapeutics pay out the dividend?

The dividends of Calliditas Therapeutics are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Calliditas Therapeutics

Our stock analysis for Calliditas Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calliditas Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.